Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04304508 · ClinicalTrials.gov registry record · Phase 2
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
A Phase 2 study of Acute Non-cardioembolic Ischemic Stroke, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,808
- Enrollment target
- 20
- Study locations
NCT04304508: Completed Phase 2 study of Acute Non-cardioembolic Ischemic Stroke, sponsored by Bayer.
NCT04304508 is a Phase 2 study of Acute Non-cardioembolic Ischemic Stroke that has completed, run by Bayer. The registered enrollment target is 1,808 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1259% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04304508, a Phase 2 study of Acute Non-cardioembolic Ischemic Stroke, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,808 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Primary Outcome
Ischemic stroke was defined as either of : 1) Rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\>24 hours symptoms/signs) or imaging evidence of infarction that was not attributable to a non-ischemic cause; 2) Acute worsening of an existing focal neurological deficit that was judged to be attributable to a new infarction or extension of the previous infarction in the same vascular territory, based on persisting symptoms/signs or imaging evidence of infarct
Conditions Studied
Interventions
- DRUG BAY2433334
- OTHER BAY2433334 matching placebo
Study Locations (20)
Victoria
- Grampians Health Ballarat - Ballarat
- Eastern Clinical Research Unit - Box Hill - Box Hill
- Royal Melbourne Hospital - Parkville
- The Alfred Hospital - Prahran
New South Wales
- Liverpool Hospital - Liverpool
- John Hunter Hospital - New Lambton
- Royal North Shore Hospital - Sydney
Queensland
- Sunshine Coast University Hospital - Birtinya
- Gold Coast University Hospital - Southport
Florida
- Univ.of South Florida College of Medicine - Tampa
Minnesota
- Minneapolis Clinic of Neurology, Ltd. - Golden Valley
Missouri
- St. Luke's Hospital of Kansas City - Kansas City
North Carolina
- Guilford Neurologic Associates - Greensboro
Pennsylvania
- University of Pittsburgh Medical Center Hamot - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,808 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 2 |
What the finished NCT04304508 record still lists
NCT04304508 is an interventional study that assigns participants to a tested intervention. Its 1,808 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1259% higher).
The record links to 1 condition, with Acute Non-cardioembolic Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which BAY2433334 is the first listed.
NCT04304508 names 20 study sites across 14 states, led by Victoria, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT04304508 about?
NCT04304508 is a clinical study titled "Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.". The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed i...
What is the current status of trial NCT04304508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,808 participants. The study started on 2020-06-15. Estimated completion is 2022-02-18.
What conditions does trial NCT04304508 study?
This clinical trial studies the following conditions: Acute Non-cardioembolic Ischemic Stroke.
What interventions are being tested in trial NCT04304508?
The interventions under investigation include: BAY2433334 (DRUG), BAY2433334 matching placebo (OTHER).
Who is sponsoring clinical trial NCT04304508?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04304508 being conducted?
This trial has 20 study locations across Florida, Minnesota, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Non-cardioembolic Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04304508's enrollment target sits among peer trials
1,808 10th of 2000 higher than 1,991 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI